Stephanie C. Casey Parks obtained her B.S. in Microbiology, Immunology, and Molecular Genetics from UCLA. She then completed her PhD in cancer biology from UC Irvine, where she worked on nuclear hormone receptor biology and oncogenesis. She then performed her postdoctoral work at Stanford University, where she studied the role of the MYC oncogene in modulating the anti-tumor immune response using genetically engineered mouse models. In 2017, Stephanie joined Amgen’s department of Oncology. At Amgen, her group works to understand the in vivo biology of emerging targets, characterize the pharmacodynamic and efficacy responses to new molecules, and create new syngeneic and humanized models to evaluate novel questions. Stephanie’s research interests include both discovery and translational oncology research, spanning from tumor-intrinsic biology to immuno-oncology and the tumor microenvironment.